Approximately 5% to 10% of fractures result in non-unions.*23 While estimates for the average non-union* treatment cost vary — from nearly $25,00024 to $45,00025 — EXOGEN has been shown to reduce fracture treatment costs by as much as $15,000.24
Whether you want to help workers get back on the job faster or simply reduce costs for treating fractures, EXOGEN may be the right choice for you and the patients you serve.
In a statistical simulation, a group of researchers put EXOGEN up against other fracture stimulation devices and calculated the expected cost of treating a non-union* fracture with each, taking into account the probability of success based on clinical evidence.26
In the end, EXOGEN was shown to be the most cost-effective treatment for non-union* fractures. Researchers determined that EXOGEN was the optimal bone treatment system for 85%26 of patients, with an expected fracture treatment cost of $6,610.26 Expected costs for other systems were 24% to 44% higher.26
EXOGEN has also been shown to help speed healing of indicated* fresh fractures by 38%2,12 and may accelerate healing in patients with certain risk factors, including obesity, advanced age and tobacco use — the latter by as much as 50%.11
Keeping fracture management costs down is important to you, to your company and to patients, who ultimately feel the impact of healthcare spending. Ready to learn more about how EXOGEN may help you reduce those expenses? Get more details in our white paper or contact your local payer representative today.
Want to talk with an EXOGEN expert? Or learn about earning CEUs through Smith & Nephew? Contact your representative today.
Call our customer service specialists at (800) 836-4080 or contact us on the web today.
Find out how EXOGEN could help you reduce healthcare costs in our just-the-facts white paper.
Browse more resources
*Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions† excluding skull and vertebra.
In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization.
There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-836-4080.
†A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
Countries 